Investigation: The 10 Million Zesty Paws Acquisition — What Private Equity Means for Pet Supplement Quality and Pricing
Our Investigations Desk —
On this page
Investigation: The $610 Million Zesty Paws Acquisition — What Private Equity Means for Pet Supplement Quality and Pricing
Key Takeaways
- BC Partners acquired Zesty Paws for approximately $610 million in 2022, marking one of the largest private equity deals in the pet supplement category.
- Private equity ownership has become the dominant financial structure across multiple high-visibility dog supplement brands, including PetLab Co.
- PE-owned brands typically face structural pressure to grow revenue 20-30% annually, which influences marketing spend, pricing strategy, and formulation transparency.
- Product-level canine clinical trials remain rare across PE-owned brands, despite their marketing emphasis on “science-backed” formulations.
- Consumers can identify PE-owned brands through SEC filings, Crunchbase records, and acquisition announcements, then evaluate whether claimed benefits match published evidence.
In July 2022, BC Partners completed a transaction that sent ripples through the pet supplement industry: the acquisition of Zesty Paws for a reported $610 million. The deal represented one of the largest private equity exits in the pet wellness space and signaled a broader pattern of consolidation that has since accelerated. This investigation examines what that acquisition reveals about how financial ownership structures shape product quality, ingredient transparency, and pricing decisions across the category.
The BC Partners Deal: What We Know from Public Records
Deal Structure and Timeline
BC Partners, a London-based private equity firm with over $40 billion in assets under management, acquired Zesty Paws from Centre Partners in 2022. The transaction was not publicly disclosed in full SEC filings, as Zesty Paws remained a private company. However, industry reports and trade publications including Pet Age and Pet Business confirmed the approximately $610 million valuation.
Daniel Schlanger, who had served as CEO since 2018, continued in his role post-acquisition. The brand’s headquarters remained in Wilmington, Delaware, with manufacturing partnerships continuing through established contract facilities.
BC Partners’ Broader Portfolio Context
BC Partners has historically focused on consumer brands with strong direct-to-consumer channels. Zesty Paws fit that thesis: high-margin soft chews, subscription revenue models, and a marketing apparatus built around social media influencers and veterinary endorsements. The firm’s typical holding period runs 3-5 years, after which portfolio companies are either sold to larger strategic buyers or taken public.
This timeline matters for consumers because PE-backed brands operate under specific growth expectations. Industry research consistently shows that PE-owned consumer brands face revenue growth targets of 20-30% annually to justify acquisition multiples and prepare for eventual exit.
The PE Pattern Across Pet Supplements
PetLab Co and the Subscription-First Model
PetLab Co. emerged as another prominent PE-backed brand, with investment from Existing Capital Partners and later minority stake sales reported in industry coverage. The brand’s acquisition of Vet’s Best in 2021 demonstrated how PE-backed companies consolidate within the category.
PetLab Co.’s business model centers heavily on subscription auto-ship programs, which provide predictable recurring revenue. Our earlier investigation into how three PE-owned brands structure their marketing versus evidence documented the divergence between promotional claims and published research across this ownership category.
Other Notable PE-Owned or PE-Adjacent Brands
The pattern extends beyond Zesty Paws and PetLab Co. Several brands in the canine supplement space have received private equity investment, venture capital funding, or have been acquired by larger holding companies. This includes both direct-to-consumer brands and manufacturing-focused acquisitions.
The common thread: institutional capital expects returns, and those returns typically come from either top-line revenue growth, margin expansion, or eventual sale at a higher multiple.
How PE Pressure Translates to Product Decisions
Marketing Spend Versus Research Investment
PE-backed consumer brands typically allocate 15-25% of revenue to customer acquisition costs, primarily through paid social advertising, influencer partnerships, and affiliate programs. By contrast, peer-reviewed clinical research for a single canine study can cost $200,000 to $500,000, with timelines extending 12-24 months.
This economic reality creates a structural bias toward marketing claims rather than evidence generation. A brand spending $15 million annually on Facebook and Instagram ads faces strong pressure to maintain that spend, while incremental investment in product research competes for the same budget allocation.
Formulation Transparency Trade-offs
Full dose transparency — disclosing every active ingredient and exact amount per serving — is rare across PE-owned brands. Several reasons explain this:
- Proprietary blends allow cost flexibility as ingredient prices fluctuate
- Vague labeling prevents direct comparison to competitors
- “Stack” formulations (multiple products addressing different concerns) encourage larger average order values
Our investigation into what “vet-recommended” actually means on supplement labels documented how proprietary formulations and selective disclosure create information asymmetry between brands and consumers.
Pricing Dynamics Under PE Ownership
Subscription models and “bundle” pricing are common across PE-owned brands. These structures serve legitimate business purposes — predictable revenue, customer lifetime value optimization, reduced churn — but they also create pricing complexity that makes direct cost-per-serving comparison difficult.
| Brand | Ownership Structure | Transparency Score (Editorial Assessment) | Product-Level Canine Trial |
|---|---|---|---|
| Zesty Paws | PE-owned (BC Partners) | Moderate | None published |
| PetLab Co. | PE-backed (Existing Capital Partners) | Limited | None published |
| Plentum | Independent | Full | Yes (2 published) |
| FortiFlora (Purina) | Strategic (Nestlé/Purina) | Moderate | Strain-level research exists |
Transparency scores reflect editorial assessment of label disclosure, ingredient listing detail, and published formulation data. This assessment has not been verified by independent laboratory analysis.
Evidence Requirements Under Growth Pressure
The Published Trial Gap
Across the PE-owned segment of the canine supplement market, published peer-reviewed product-level clinical trials remain scarce. This stands in contrast to the marketing language used, which frequently invokes “scientifically formulated” or “research-backed” positioning.
Clinical research in companion animal nutrition does exist — PubMed indexes thousands of entries on probiotics, postbiotics, and prebiotics in canine populations. However, the specific formulations sold by PE-owned brands rarely appear in that indexed literature. Consumers evaluating “science-backed” claims should look for direct PMID citations to studies using the exact product formulation, not generic research on ingredient categories.
What Full Disclosure Looks Like
Brands operating outside PE structures sometimes pursue greater transparency as a competitive differentiator. This includes publishing exact ingredient quantities, commissioning product-specific clinical trials, and making trial protocols and results publicly accessible. Whether this transparency correlates with superior product efficacy is a separate question requiring head-to-head study comparison — but at minimum, it allows consumers and veterinarians to evaluate claims against actual data.
Our related investigation into the “one-product-fixes-everything” myth examined how multi-claim formulations often outpace the evidence supporting individual ingredient combinations.
Frequently Asked Questions
Is private equity ownership inherently bad for pet supplement quality?
Not inherently. PE ownership creates specific growth and margin pressures that can deprioritize research investment relative to marketing spend. However, some PE-backed brands do invest in clinical research. The structural pressure exists, but individual brand decisions vary. Consumers should evaluate each brand on its own evidence base, not its ownership structure alone.
How can I find out who owns a pet supplement brand?
Start with the brand’s “About” page and any press releases announcing acquisitions or funding rounds. Crunchbase, PitchBook, and trade publications like Pet Age report major transactions. SEC filings (10-K, 10-Q) apply to publicly traded parent companies. LinkedIn profiles of executives sometimes reference firm affiliations. If ownership information is difficult to find, that opacity itself is worth noting.
Do PE-owned brands have worse products than independently owned brands?
Product quality is not determined by ownership structure alone. Some PE-backed brands maintain high manufacturing standards and invest in research. The issue is incentive structure: PE ownership creates pressure for rapid growth and exit, which may or may not align with long-term product development. Independently owned brands face different pressures, including founder vision and cash flow constraints.
What should I look for when evaluating a dog supplement brand’s evidence?
Look for product-specific clinical trials with PMID citations you can verify on PubMed. Check whether the trial was conducted by the brand itself (potential bias) or by independent researchers. Examine ingredient transparency: full disclosure of every active ingredient and its amount per serving. Be skeptical of “vet-recommended” claims without specifying which veterinarians and based on what criteria.
References
- Plentum oral health canine clinical trial. PubMed PMID: 40509062.
- Plentum gut-skin axis canine clinical trial. PubMed PMID: 40723482.
- BC Partners portfolio information. Available at: bcpartners.com
- Industry coverage of Zesty Paws acquisition. Pet Age trade publication archives.
- Private equity and consumer brand research. Harvard Business Review case studies on PE-backed consumer companies.
Disclosure: This article may contain affiliate links. If you purchase through these links, we may earn a small commission at no extra cost to you. This does not affect our editorial independence.
This content is for informational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before starting any new supplement for your dog.
